CN85102133A - 2—硝基氧甲基—6—氯吡啶与β—环糊精的吸留化合物制备方法 - Google Patents

2—硝基氧甲基—6—氯吡啶与β—环糊精的吸留化合物制备方法 Download PDF

Info

Publication number
CN85102133A
CN85102133A CN198585102133A CN85102133A CN85102133A CN 85102133 A CN85102133 A CN 85102133A CN 198585102133 A CN198585102133 A CN 198585102133A CN 85102133 A CN85102133 A CN 85102133A CN 85102133 A CN85102133 A CN 85102133A
Authority
CN
China
Prior art keywords
nitroxymethyl
chloropyridine
occluded
beta
cyclodextrin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN198585102133A
Other languages
English (en)
Inventor
上田芳雄
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fujisawa Pharmaceutical Co Ltd
Original Assignee
Fujisawa Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujisawa Pharmaceutical Co Ltd filed Critical Fujisawa Pharmaceutical Co Ltd
Publication of CN85102133A publication Critical patent/CN85102133A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
    • C08B37/0015—Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Nanotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Materials Engineering (AREA)
  • Polymers & Plastics (AREA)
  • Zoology (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Cardiology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Pyridine Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Saccharide Compounds (AREA)

Abstract

在本申请中公开了2—硝基氧甲基—6—氯吡啶与β—环糊精的吸留化合物及其制备方法。其中2—硝基氧甲基—6—氯吡啶与β—环糊精的摩尔比在约1∶1和约3∶1之间。该吸留化合物是不挥发的，因此，为了制备药剂，要克服与2—硝基氧甲基—6—氯吡啶的挥发性有关的问题。本发明的方法是通过2—硝基氧甲基—6—氯吡啶与β—环糊精反应来完成的，或是通过两个化合物与少量的溶剂捏和，或是通过两个化合物在适宜的溶剂例如水中混合。然后该吸留化合物用常规的方法沉淀，分离和进一步纯化。

Description

本发明是关于2-硝基氧甲基-6-氯吡啶与β-环糊精的吸留化合物及其制备方法。
2-硝基氧甲基-6-氯吡啶是具有下面结构式的化合物，并用于医治血管病。
Figure 85102133_IMG1
2-硝基氧甲基-6-氯吡啶是油性的和易挥发的物质。通常把这样的物质制成药剂是困难的。
为了克服上述困难通过深入的研究，本发明者发现用2-硝基氧甲基-6-氯吡啶与β-环糊精以摩尔比约为1∶1或3∶1的条件下，转变成吸留化合物可以克服上面的困难。
本发明不仅成功地解决了2-硝基氧甲基-6-氯吡啶粉剂制备的问题，而且成功地解决了防止挥发的问题。
本发明的方法是通过使2-硝基氧甲基-6-氯吡啶与β-环糊精反应来完成的。
吸留的方法包括几种改进。例如，有溶剂方法，包括宿主化合物和客体化合物同少量溶剂一起进行捏和的方法，等等。在这些方法中优先选用的是溶剂方法，该方法只需要在适宜溶剂中两种化合物相互混合。得到的吸留化合物用常规方法进行分离和纯化。例如，当吸留反应在水溶液中进行时，微溶于水的吸留化合物从反应混合物中沉淀出来。沉淀物可用常规的方法分离，例如用离心分离。这样分出的产物可用水洗纯化，从而除去了水溶性的β-环糊精或2-硝基氧甲基-6-氯吡啶。
上述方法得到的吸留化合物的特点在于防止了2-硝基氧甲基-6-氯吡啶的挥发。例如：从图5可明显的看出，图5表示2-硝基氧甲基-6-氯吡啶的残余百分数是时间的函数，在放置60分钟后，可保留100%的摩尔比为1∶1的2-硝基氧甲基-6-氯吡啶-β-环糊精吸留化合物或约87%摩尔比为3∶1的2-硝基氧甲基-6-氯吡啶-β-环糊精吸留化合物。而2-硝基氧甲基-6-氯吡啶本身在放置60分钟后，残余百分数为0%，由此清楚的看出显著地防止了2-硝基氧甲基-6-氯吡啶的挥发。
下面的实例是进一步说明本发明方法。
实例1
在5个离心分离管中分别用20ml蒸馏水溶解600mg    β-环糊精。接着向5个离心分离管中分别加入50，100，200，300和400mg2-硝基氧甲基-6-氯吡啶，摇动离心分离该混合物，然后使其在室温下静置一夜，以便完全结晶。
过滤收集结晶体，用水洗涤，然后，空气干燥得到2-硝基氧甲基-6-氯吡啶与β-环糊精的吸留化合物。
制备2-硝基氧甲基-6-氯吡啶与β-环糊精吸留化合物的条件和在产物中的摩尔比见表1。
得到的吸留化合物有下列物理性质。
（ⅰ）在它的X射线粉末衍射图中，显示出峰值在约11.5°和约18.4°。这些都是2-硝基氧甲基-6-氯吡啶与β-环糊精吸留化合物的特性。
（ⅱ）在它的红外吸收光谱中（液体石蜡），显示在3300，1645，1586，1568，1459，1376，1330，1281，1158，1080，1022，1000，940和842Cm-1处有吸收。
（ⅲ）微溶于水。
Figure 85102133_IMG2
这些产物的X-射线粉末衍射图在图1和图2表示，和红外吸收光谱在图3和图4表示。
图1和图2是按照本发明实例1中得到的吸留化合物的X射线粉末衍射图，即，摩尔比分别为1∶1和3∶1的2-硝基氧甲基-6-氯吡啶与β-环糊精吸留化合物的X射线粉末衍射图。图3和图4是本发明的吸留化合物其摩尔比分别为1∶1和3∶1时的红外吸收光谱。
图5说明了吸留化合物对2-硝基氧甲基-6-氯吡啶挥发性的影响。

Claims (2)

1、2-硝基氧甲基-6-氯吡啶与β-环糊精吸留化合物的制备方法，包括2-硝基氧甲基-6-氯吡啶与β-环糊精反应，该吸留化合物具有下列物理性质：
(i)在它的X射线粉末衍射图中，显示出2-硝基氧甲基-6-氯吡啶与β-环糊精的吸留化合物的特性峰值在11.5°，约17.2°和约18.4°。
(ii)在它的红外吸收光谱(液体石蜡)中，显示出在3300，1645，1586，1568，1459，1376，1330，1281，1158，1080，1022，1000，940和842Cm-1处有吸收。
(iii)微溶于水。
2、权项要求1的方法中，β-环糊精的水溶液与2-硝基氧甲基-6-氯吡啶混合。
CN198585102133A 1983-10-11 1985-04-01 2—硝基氧甲基—6—氯吡啶与β—环糊精的吸留化合物制备方法 Pending CN85102133A (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP58190345A JPS6081166A (ja) 1983-10-11 1983-10-11 ２−ニトロオキシメチル−６−クロロピリジンのβ−シクロデキストリン包接化合物およびその製造法

Publications (1)

Publication Number Publication Date
CN85102133A true CN85102133A (zh) 1987-01-17

Family

ID=16256648

Family Applications (1)

Application Number Title Priority Date Filing Date
CN198585102133A Pending CN85102133A (zh) 1983-10-11 1985-04-01 2—硝基氧甲基—6—氯吡啶与β—环糊精的吸留化合物制备方法

Country Status (18)

Country Link
US (1) US4575548A (zh)
EP (1) EP0141300A3 (zh)
JP (1) JPS6081166A (zh)
KR (1) KR850003414A (zh)
CN (1) CN85102133A (zh)
AU (1) AU576521B2 (zh)
CA (1) CA1248523A (zh)
DK (1) DK461184A (zh)
ES (1) ES536654A0 (zh)
FI (1) FI843944L (zh)
GR (1) GR80531B (zh)
HU (1) HU194285B (zh)
IL (1) IL73076A (zh)
NO (1) NO843773L (zh)
OA (1) OA07832A (zh)
PH (1) PH20203A (zh)
PT (1) PT79320B (zh)
ZA (1) ZA847350B (zh)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6034156A (ja) * 1983-08-08 1985-02-21 Hayashibara Biochem Lab Inc エイコサペンタエン酸包接化合物及びこれを含有した飲食物
JPS60202115A (ja) * 1984-03-27 1985-10-12 Ichiro Shibauchi エポキシ樹脂用硬化剤
ZA885069B (en) * 1987-07-24 1989-03-29 Fujisawa Pharmaceutical Co Sustained-release percutaneous preparations
US5017566A (en) * 1987-12-30 1991-05-21 University Of Florida Redox systems for brain-targeted drug delivery
US5002935A (en) * 1987-12-30 1991-03-26 University Of Florida Improvements in redox systems for brain-targeted drug delivery
CA1321192C (en) * 1988-04-20 1993-08-10 Abdul Majid Inclusion complexes of cyclodextrins by agglomeration
US5997856A (en) * 1988-10-05 1999-12-07 Chiron Corporation Method and compositions for solubilization and stabilization of polypeptides, especially proteins
US20040014695A1 (en) * 1992-06-19 2004-01-22 Supergen, Inc. Pharmaceutical formulation
US5602112A (en) * 1992-06-19 1997-02-11 Supergen, Inc. Pharmaceutical formulation
US5824668A (en) * 1996-11-07 1998-10-20 Supergen, Inc. Formulation for administration of steroid compounds
EP1176792A1 (en) * 2000-07-24 2002-01-30 Alcatel Method and apparatus for providing an all digital loop with power-optimised mode
US20070009531A1 (en) * 2005-07-06 2007-01-11 Branimir Sikic Treatment of patients with cancer using a calicheamicin-antibody conjugate in combination with zosuquidar
US20070010486A1 (en) * 2005-07-06 2007-01-11 Jeff Schwegman Chemotherapeutic formulations of zosuquidar trihydrochloride and modified cyclodextrins
US20070010485A1 (en) * 2005-07-06 2007-01-11 Jeff Schwegman Chemotherapeutic formulations of zosuquidar trihydrochloride and modified cyclodextrins
US20070010487A1 (en) * 2005-07-06 2007-01-11 Jeff Schwegman Chemotherapeutic formulations of zosuquidar trihydrochloride and modified cyclodextrins
US20070010478A1 (en) * 2005-07-06 2007-01-11 Branimir Sikic Zosuquidar, daunorubicin, and cytarabine for the treatment of cancer
US11812951B2 (en) 2008-06-17 2023-11-14 Apollo Endosurgery Us, Inc. Endoscopic needle assembly
CA2692211C (en) * 2009-12-14 2011-09-13 Cellresin Technologies, Llc Maturation or ripening inhibitor release from polymer, fiber, film, sheet or packaging
PT2690951E (pt) 2011-03-27 2015-11-25 Cellresin Tech Llc Composições de ciclodextrina, artigos, e métodos
US10182567B2 (en) 2011-03-27 2019-01-22 Cellresin Technologies, Llc Cyclodextrin compositions, articles, and methods
US9320288B2 (en) 2012-11-30 2016-04-26 Cellresin Technologies, Llc Controlled release compositions and methods of using
US9421793B2 (en) 2014-06-26 2016-08-23 Cellresin Technologies, Llc Electrostatic printing of cyclodextrin compositions

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2959580A (en) * 1956-10-17 1960-11-08 Univ Minnesota Formation of inclusion compounds
CH445129A (fr) * 1964-04-29 1967-10-15 Nestle Sa Procédé pour la préparation de composés d'inclusion à poids moléculaire élevé
JPS56123912A (en) * 1980-03-05 1981-09-29 Nitto Electric Ind Co Ltd Drug-containing tape preparation
HU182217B (en) * 1980-10-17 1983-12-28 Chinoin Gyogyszer Es Vegyeszet Process for producing inclusive complexes of cyclodextrines and strong inorganic oxyacids
JPS57142962A (en) * 1981-02-28 1982-09-03 Santen Pharmaceut Co Ltd Cyclodextrin clathrate compound of sulfur-containing compound
JPS6054304B2 (ja) * 1981-10-16 1985-11-29 株式会社バコム ジソピラミド包接化合物
US4425336A (en) * 1982-05-24 1984-01-10 Key Pharmaceuticals, Inc. 3,4-Dihydroxy-N-[3-(4-dihydroxyphenyl)-1-methyl-n-propyl]-beta-phenethylamine cyclodextrin complexes
DK311683A (da) * 1982-07-26 1984-01-27 Fujisawa Pharmaceutical Co Fremgangsmaade til fremstilling af pyridylalkylnitratforbindelser
JPS6025967A (ja) * 1983-07-21 1985-02-08 Eisai Co Ltd トリパミド包接化合物
DE3329517A1 (de) * 1983-08-16 1985-02-28 Hoechst Ag, 6230 Frankfurt Einschlussverbindung von n,n-dimethyl-2-chlor-5-(3-methyl-2-(phenylimino)-4-thiazolin-4-yl)phenylsulfonamid, verfahren zu ihrer herstellung sowie pharmazeutische praeparate
DE3337802A1 (de) * 1983-10-18 1985-04-25 Merck Patent Gmbh, 6100 Darmstadt Pharmazeutische zubereitung

Also Published As

Publication number Publication date
PT79320A (en) 1984-11-01
AU3339984A (en) 1985-04-18
DK461184A (da) 1985-04-12
NO843773L (no) 1985-04-12
AU576521B2 (en) 1988-09-01
EP0141300A2 (en) 1985-05-15
JPS6245226B2 (zh) 1987-09-25
ZA847350B (en) 1985-10-30
ES8506758A1 (es) 1985-08-01
DK461184D0 (da) 1984-09-26
US4575548A (en) 1986-03-11
OA07832A (fr) 1986-11-20
JPS6081166A (ja) 1985-05-09
HUT36832A (en) 1985-10-28
GR80531B (en) 1985-01-09
IL73076A (en) 1988-05-31
EP0141300A3 (en) 1986-01-29
HU194285B (en) 1988-01-28
PH20203A (en) 1986-10-20
KR850003414A (ko) 1985-06-17
FI843944A0 (fi) 1984-10-08
IL73076A0 (en) 1984-12-31
CA1248523A (en) 1989-01-10
ES536654A0 (es) 1985-08-01
FI843944L (fi) 1985-04-12
PT79320B (en) 1986-09-08

Similar Documents

Publication Publication Date Title
CN85102133A (zh) 2—硝基氧甲基—6—氯吡啶与β—环糊精的吸留化合物制备方法
DE60209516T2 (de) Prozess zur Herstellung kristalliner Partikel von Fluticason, Beclomethason, Salmeterol und Salbutamol
RU2126397C1 (ru) СПОСОБ ПОЛУЧЕНИЯ ТРИГИДРАТА (2R, 3S)-3-ТРЕТ-БУТОКСИ-КАРБОНИЛАМИНО-2-ГИДРОКСИ-3- ФЕНИЛПРОПИОНАТА-4-АЦЕТОКСИ -2α- БЕНЗОИЛОКСИ -5β, 20-ЭПОКСИ -1,7β,10β- ТРИГИДРОКСИ-9-ОКСО- ТАКС-11-ЕН-13α-ИЛА
JP3511144B2 (ja) 促進剤系の貯蔵安定性溶液
DE60022147T2 (de) Organophosphor- Zusammensetzung, Verfahren zur Herstellung einer Organophosphor-Verbindung, Polyester-Zusammensetzung und Verfahren zur Herstellung davon
JP2785018B2 (ja) 二酸化第二セリウムをアルコール中に分散させてなるコロイド分散体の製造方法
Jernakoff et al. Hydrolysis of the metal-chloride bonds in (. eta. 5-C5Me5) TaCl4 leading to stepwise formation of binuclear and trinuclear tantalum oxide clusters
DE69226578T2 (de) Production eines Zellulosederivates
DE2802485A1 (de) Koordinationskomplexe von metallhalogeniden mit siliciumhaltigen verbindungen und deren verwendung
JPS63280100A (ja) 結晶性ヒトプロインシュリンおよびその製造方法
JPH0643429B2 (ja) 高度に結晶性のナトリウムセフオペラゾンの製法
US5144050A (en) Ruthenium(II)-BINAP diketonate complexes
JPH0528221B2 (zh)
EP3059226A1 (en) 2-amino-2-[2-[4-(3-benzyloxyphenylthio)-2-chlorophenyl]-ethyl]-1,3-propanediol hydrochloride crystal
DE69804525T2 (de) Chirale Träger und deren Verwendung in der Hertsellung oder Trennung von Enantiomeren
JPH02229198A (ja) カリックスアレーン誘導体
CN1176895C (zh) 制备山梨酸的方法
Uson et al. Neutral bis (pentafluorophenyl) triphenylarsinegold (III) complexes
CN1028029C (zh) 聚酰胺或聚酯酰胺热熔胶粉的制造方法
US3057678A (en) Preparation of zirconyl chloride octahydrate
DE3739174A1 (de) Kondensierte acetessigsaeureester-titanchelate und verfahren zu deren herstellung
CN1044455A (zh) 2，2，-二(1，6，7-三羟基-3-甲基-5-异丙基-8-萘甲醛)的纯化方法
DE2461470A1 (de) Polymere alkoxide auf der basis von hydroxyalkylmethacrylaten und ihr herstellungsverfahren
DE3137840A1 (de) Zirkonmethacrylat, verfahren zu seiner herstellung und anwendung als vernetzungsmittel
KR100240479B1 (ko) 금 카르복실산염과 그 제조방법

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination